As of 2025-05-31, the Intrinsic Value of NeuBase Therapeutics Inc (NBSE) is -18.31 USD. This NBSE valuation is based on the model Peter Lynch Fair Value. With the current market price of 0.38 USD, the upside of NeuBase Therapeutics Inc is -4,943.03%.
Based on its market price of 0.38 USD and our intrinsic valuation, NeuBase Therapeutics Inc (NBSE) is overvalued by 4,943.03%.
Note: result may not be accurate due to the invalid valuation result of Peter Lynch's fair value model.
| Range | Selected | Upside | |
| a | |||
| Fair Value | -18.31 - -18.31 | -18.31 | -4,943.03% |
| P/E | (4.76) - (53.09) | (29.47) | -7897.3% |
| DDM - Stable | (26.86) - (89.71) | (58.29) | -15519.6% |
| DDM - Multi | (2.73) - (7.21) | (3.97) | -1151.4% |
| Market Cap (mil) | 1.42 |
| Beta | 1.55 |
| Outstanding shares (mil) | 3.75 |
| Enterprise Value (mil) | -11.15 |
| Market risk premium | 4.60% |
| Cost of Equity | 10.52% |
| Cost of Debt | 5.00% |
| WACC | 10.16% |